Sanctuary Advisors LLC Takes Position in Prestige Consumer Healthcare Inc. $PBH

Sanctuary Advisors LLC acquired a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 14,407 shares of the company’s stock, valued at approximately $681,000.

Several other large investors also recently made changes to their positions in the company. Lido Advisors LLC increased its position in Prestige Consumer Healthcare by 5.4% in the 4th quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock valued at $235,000 after acquiring an additional 192 shares during the period. Cerity Partners LLC raised its position in Prestige Consumer Healthcare by 5.9% in the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after acquiring an additional 218 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares in the last quarter. Versant Capital Management Inc boosted its holdings in Prestige Consumer Healthcare by 47.9% during the second quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock worth $34,000 after buying an additional 235 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after buying an additional 236 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Key Headlines Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Attractive value profile: A Zacks comparison of PBH and Stryker (SYK) highlights the value-investing case for Prestige Consumer Healthcare. PBH’s lower earnings multiple and defensive consumer-healthcare portfolio could support investor interest, although the comparison does not guarantee that PBH is the superior investment. PBH vs. SYK: Which Stock Is the Better Value Option?
• Positive Sentiment: Longer-term earnings growth: Zacks Research projects EPS of $4.55 for fiscal 2027, rising to $5.06 in fiscal 2028 and $5.25 in fiscal 2029. The forecasts imply improving earnings power and provide a potential catalyst if the company delivers.
• Neutral Sentiment: Quarterly estimates remain steady: Zacks forecasts EPS of $1.06 for fiscal Q2 2027, $1.22 for Q3 and $1.30 for Q4, followed by estimates of $1.14, $1.19, $1.38 and $1.35 for fiscal 2028’s quarters. These projections indicate expectations for consistent profitability rather than a near-term earnings surprise.
• Negative Sentiment: Analyst stance is cautious: Zacks Research maintains a “Hold” rating, and its fiscal 2027 EPS forecast of $4.55 is essentially in line with the $4.56 consensus estimate. That suggests the expected earnings growth is largely recognized in current expectations, limiting an immediate upgrade catalyst.

Analyst Ratings Changes

Several brokerages have recently commented on PBH. Canaccord Genuity Group reduced their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, August 10th. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Stock Performance

NYSE PBH opened at $52.48 on Friday. Prestige Consumer Healthcare Inc. has a 52-week low of $42.62 and a 52-week high of $71.07. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of 14.70, a P/E/G ratio of 1.61 and a beta of 0.34. The company’s fifty day moving average is $50.22 and its two-hundred day moving average is $54.62. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. The firm had revenue of $265.71 million for the quarter, compared to analyst estimates of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business’s revenue for the quarter was up 6.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).